BUMRUNGRAD HOSPITAL Plc. (BH): Earnings In Line; Special Dividend Announced
4Q25 NP was Bt1.9bn, down 1% YoY and 7% QoQ, in line with our and market expectations. YoY, EBIT rose 7%, but higher tax expenses of Bt424mn (vs...
148 Views
BUMRUNGRAD HOSPITAL Plc. (BH): 4Q25E Core Profit Beats Earlier View On Stronger GPM
We expect 4Q25E core profit to grow YoY, reversing our earlier view of a slight YoY decline, driven by stronger-than-expected GPM.
133 Views
Primer: Bumrungrad Hospital Pub Co (BH TB) - Jan 2026
Leading Player in a High-Growth Niche: Bumrungrad is a premier private healthcare provider in Southeast Asia, strategically positioned to...
148 Views
APAC Healthcare Weekly (August 9) – Hengrui, CSPC Pharma, Takeda Pharma, Otsuka, Alteogen
Hengrui’s trastuzumab rezetecan got 3rd indication approval in China. CSPC and AstraZeneca form JV for biologics manufacturing facility in China....
122 Views
BUMRUNGRAD HOSPITAL Plc. (BH): International Patient Trend Showing Signs Of Improvement
We upgrade our rating to Neutral (from Underperform) and roll forward our target price to 2026E at Bt166.00, based on a required return of 5.6% and...
202 Views